AInvest★★★★★3-DAY FREE
Catch pre-market movers with AI signals.
Claim Trial
YMAB(Quitar la ciudad)
Y-mAbs Therapeutics·NASDAQ
--
--(--)
Y-mAbs Therapeutics (YMAB) Financial Statements
Y-mAbs Therapeutics (YMAB) Cash Flow Statement
During Q1 2024, Y-mAbs Therapeutics (YMAB) generated -3.48M in cash flow from operating activities, -- from investing activities, and 588.00K from financing activities. Click to view the cash flow statement and track how funds are moving through the company.
Cash Flow
Q1,2018 | Q1,2019 | Q1,2020 | Q1,2021 | Q1,2022 | Q1,2023 | Q1,2024 | TTM |
|---|
Start Date | Jan 1, 2018 | Jan 1, 2019 | Jan 1, 2020 | Jan 1, 2021 | Jan 1, 2022 | Jan 1, 2023 | Jan 1, 2024 | -- |
End Date | Mar 31, 2018 | Mar 31, 2019 | Mar 31, 2020 | Mar 31, 2021 | Mar 31, 2022 | Mar 31, 2023 | Mar 31, 2024 | -- |
Fiscal Year-End | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | -- |
Net Cash Flows from Operating Activities | -6.61M -- | -13.48M -104.04% | -21.76M -61.36% | -31.86M -46.45% | -24.93M +21.77% | -13.12M +47.35% | -3.48M +73.51% | -- -- |
Depreciation and Amortization | -- -- | 19.00K -- | 86.00K +352.63% | 130.00K +51.16% | 195.00K +50.00% | 182.00K -6.67% | 159.00K -12.64% | -- -- |
Change in Working Capital | 852.00K -- | 712.00K -16.43% | 2.49M +249.44% | -8.38M -436.86% | -2.88M +65.67% | -11.76M -308.90% | -1.34M +88.57% | -- -- |
Net Cash Flows from Investing Activities | -- -- | -126.00K -- | -26.00K +79.37% | 61.61M +237061.54% | -- -- | -- -- | -- -- | -- -- |
Purchase of PPE and Intangible Assets | -- -- | 126.00K -- | 26.00K -79.37% | 400.00K +1438.46% | -- -- | -- -- | -- -- | -- -- |
Net Cash Flows from Financing Activities | -1.64M -- | -- -- | 370.00K -- | 107.83M +29044.59% | 32.00K -99.97% | -- -- | 588.00K -- | -- -- |
Change in Capital Stock | -- -- | -- -- | -- -- | 107.72M -- | -- -- | -- -- | -- -- | -- -- |
Increase in Capital Stock | -- -- | -- -- | -- -- | 107.72M -- | -- -- | -- -- | -- -- | -- -- |
Effect of Foreign Exchange Rate Changes | -20.00K -- | 13.00K +165.00% | 50.00K +284.62% | 53.00K +6.00% | 53.00K -- | -9.00K -116.98% | 1.00K +111.11% | -- -- |
Net Increase in Cash and Cash Equivalents | -8.27M -- | -13.60M -64.42% | -21.36M -57.12% | 137.64M +744.31% | -24.84M -118.05% | -13.13M +47.13% | -2.89M +78.01% | -- -- |
Cash and Cash Equivalents at Beginning of Period | 90.52M -- | 147.87M +63.37% | 207.14M +40.08% | 114.63M -44.66% | 181.56M +58.39% | 105.76M -41.75% | 78.64M -25.65% | -- -- |
Cash and Cash Equivalents at End of Period | 82.25M -- | 134.28M +63.26% | 185.77M +38.35% | 252.27M +35.79% | 156.72M -37.87% | 92.63M -40.90% | 75.75M -18.22% | -- -- |
You can ask Aime
No Data
